Literature DB >> 2471750

Complement activation and endotoxin levels in systemic meningococcal disease.

P Brandtzaeg1, T E Mollnes, P Kierulf.   

Abstract

The activation state of the complement system in 39 consecutively admitted patients with systemic meningococcal disease was studied prospectively using two monoclonal antibodies reacting with neoepitopes exposed during complement activation. The fluid-phase C3 activation products and SC5b-9 (terminal complement complex) were strongly correlated to the levels of endotoxin (lipooligosaccharides, LOS) in plasma on admission (r = .79, P less than .0001 and r = .76, P less than .0001, respectively) and to fatality. Maximum complement activation in survivors occurred 7h (median; range 0-44 h) after initiation of antibiotic treatment. The most severely ill patients had the capacity to activate the whole complement cascade. In nonsurvivors, high-grade activation often continued until the patients died. The results suggest that LOS are important activators of complement in systemic meningococcal disease and that complement-activating products, in concert with other mediators, may contribute to the multiple organ failure and death occurring in the most severe cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471750     DOI: 10.1093/infdis/160.1.58

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

2.  High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA.

Authors:  Z Zhu; T P Atkinson; K T Hovanky; S B Boppana; Y L Dai; P Densen; R C Go; J S Jablecki; J E Volanakis
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 3.  Complement deficiencies and meningococcal disease.

Authors:  P Densen
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

4.  Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.

Authors:  A F Verheul; G J Boons; G A Van der Marel; J H Van Boom; H J Jennings; H Snippe; J Verhoef; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation.

Authors:  Bernt Christian Hellerud; Jørgen Stenvik; Terje Espevik; John D Lambris; Tom Eirik Mollnes; Petter Brandtzaeg
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

6.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Phage antibodies obtained by competitive selection on complement-resistant Moraxella (Branhamella) catarrhalis recognize the high-molecular-weight outer membrane protein.

Authors:  E Boel; H Bootsma; J de Kruif; M Jansze; K L Klingman; H van Dijk; T Logtenberg
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

8.  Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy.

Authors:  P Brandtzaeg; K Bryn; P Kierulf; R Ovstebø; E Namork; B Aase; E Jantzen
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

9.  Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation.

Authors:  C M Verduin; M Jansze; C Hol; T E Mollnes; J Verhoef; H van Dijk
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

10.  Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern.

Authors:  J P de Boer; A A Creasey; A Chang; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.